We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Amorcyte, Inc. has announced the completion of the phase I clinical trial of its lead product, AMR-001 – an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI).

“All treatment patients in each dose cohort of the phase I trial received intra-coronary artery infusion of a specified number of stem cells. The number of stem cells infused was increased over the previous cohort”, said Dr. Thomas Moss, Amorcyte’s Chief Medical Officer.

“We are excited to have completed the phase I clinical trial of AMR-001 in patients with acute myocardial infarction (AMI), or heart attack, who have suffered significant damage to their heart muscle,” stated Arshed A. Quyyumi, MD, FRCP, FACC, Professor of Medicine, Cardiology, at Emory University School of Medicine and the trial’s principal investigator.

“This trial has demonstrated proof of principle for this type of cell-based therapy. We have shown that it is possible to take progenitor stem cells harvested and extracted from a patient’s bone marrow shortly after a heart attack and deliver these cells back into the patient’s heart with the intent of repairing the damaged heart muscle. We eagerly anticipate beginning a phase II trial”.